Last updated: 2026-09-08 11:37:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Celcuity Inc. (CELC) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $95,17, with a market capitalization of $4,68B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $44,42 to $151,02. This page covers its latest market performance, valuation, price trends and company information.
$4,68B | |
$94,08 | |
$151,02 | |
$4,03 | |
-- | |
277,00 | |
1,26M | |
-- | |
$151,02 | |
$44,42 | |
-- | |
-- |
Celcuity Inc. (CELC) is trading at $96,90 in pre-market trading as of 2026-09-08 11:25:00, -- from the previous close of $0,00
Pre-market trading shows how investors are pricing CELC before the regular session opens. The current pre-market price is -- the previous close, indicating positive early trading sentiment.
Over the past seven days, Celcuity Inc. (CELC) moved from $93,24 to $95,17, representing a gain of 2,06% ($1,93).
The stock traded between $86,99 and $98,00 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 736,64 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 47,6%
CELC is currently trading at $95,17, placing it 47,6% of the way from its 52-week low of $44,42 to its 52-week high of $151,02. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 155 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Celcuity Inc. (CELC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.